Primotec: Shinzon, the Goodwill That Was Not Written Down, and the Assumptions Still Needing Proof
Shinzon ended 2025 with an ongoing operating loss, backlog down to NIS 18.2 million, and unchanged goodwill of NIS 4.771 million. This follow-up shows that the impairment cushion stayed positive, but only on a value-in-use model and growth assumptions that still need to be proven through actual project economics.
What This Follow-Up Isolates
The main article argued that Primotec moved in 2025 from an easy defense-tailwind story to a proof year. This follow-up isolates a different layer, smaller in revenue terms but sharp in reporting quality terms: Shinzon still runs at an operating loss, and yet the goodwill attached to it, NIS 4.771 million, was not written down.
This is not a footnote. On one side there is a real activity with backlog of NIS 18.2 million at year-end 2025 and NIS 16.5 million near the report date. On the other, keeping the goodwill on the balance sheet depends on a value-in-use model with a five-year growth path. So the right question is not whether Shinzon exists or whether it has projects. The right question is what has actually been proven already, and what still rests on assumptions.
That matters now because Shinzon already failed one test that was embedded in the original deal structure. The contingent consideration of up to NIS 0.57 million, linked to an average EBITDA target for 2022 through 2024, never vested. In other words, one part of the original deal logic did not clear its own profitability hurdle. Even so, 2025 ended without another impairment.
What Was Actually Bought
To understand why the goodwill is sensitive, the acquisition itself matters. Primotec signed the deal in October 2021 to acquire all of Shinzon for up to NIS 16.3 million, but the deal closed in January 2022 only after Shinzon's real-estate assets and investment-property assets were transferred to the sellers. After that adjustment, the consideration fell to up to about NIS 12.59 million.
That is a material detail. Primotec did not buy an activity with a real-estate cushion behind it. It bought a project business, without a property layer that could later explain part of the value. Out of the adjusted consideration, about NIS 9.45 million was paid at closing, about NIS 2.57 million was paid later in installments, and the final piece, up to NIS 0.57 million, was contingent on the average EBITDA target that was not met.
The deal also included temporary transition layers. The sellers, who had been part of Shinzon's management team, were required to provide professional services for up to three years from closing. They also agreed not to compete in the public-projects market for four years. The analytical implication is straightforward: part of the protection package in the deal was temporary from day one. By the time the 2025 filing tests whether the goodwill still holds, the read depends much more on the stand-alone economics of the activity and much less on the original seller bridge.
| Deal component | What the filing says | Why it matters to the 2025 read |
|---|---|---|
| Original maximum consideration | Up to NIS 16.3m | That was the headline price before adjustments |
| Adjusted consideration after the property transfer | Up to about NIS 12.59m | The deal remained an operating-business acquisition, not an asset-backed one |
| Paid at closing | About NIS 9.45m | Most of the cash went out upfront |
| Deferred consideration | About NIS 2.57m | Part of the deal economics was spread across the transition period |
| Contingent consideration | Up to NIS 0.57m | It was not paid, because the 2022-2024 average EBITDA hurdle was not reached |
| Seller services and non-compete | Up to 3 years of services, 4 years of public-project non-compete | Transitional support, not a permanent moat |
The Goodwill Survived, but the Cushion Is Thin
The filing does not present Shinzon as an activity that has already turned operationally cleaner. Quite the opposite. Note 10 states explicitly that an ongoing operating loss at Shinzon was a warning sign for impairment. That is why the company tested the recoverable amount already as of June 30, 2025, and then again in the annual year-end review as of December 31, 2025.
The original gross goodwill allocated to Shinzon stood at NIS 6.399 million. In 2024 the company already recorded a NIS 1.628 million impairment against it. By the end of 2025, the net goodwill remained at NIS 4.771 million, exactly where it stood at the end of 2024. In other words, the haircut already taken did not widen, but neither did 2025 deliver clean new proof that would make the debate go away.
In the 2025 annual test, the recoverable amount of the unit was estimated at NIS 16.147 million, versus a carrying value of NIS 14.532 million. That is headroom of only about NIS 1.615 million. It is positive, and that is why no further impairment was booked. But it is not wide.
The model assumptions matter just as much. The test uses five years of forecast cash flows with a pre-tax discount rate of 19.95%, down from 22.84% in 2024. The valuation disclosure also lays out a yearly revenue-growth path of 7.6% in 2026, 15% in 2027, 8% in 2028, 5% in 2029, and 3% in 2030. On average, that is about 7.7% revenue growth across the period, converging to a representative-year growth rate of 3%.
That is the core of the follow-up. The goodwill did not survive because the operating proof is already clean and obvious. It survived because the valuation model still produces a recoverable amount above carrying value. That distinction matters. On the accounting line, the company is correct: the cushion is positive. On the analytical line, it is still a cushion that asks the reader to believe in future improvement in an activity that the filing still describes through an ongoing operating loss.
The Real Issue Is Project Economics, Not Only Accounting
The mistake would be to read Shinzon only through the goodwill note. The issue is not only accounting. It is economic. Section 7.5.3 describes a short-cycle project business, usually a few months to two years, with a signed agreement, product specifications, installation services, timelines, and consideration that is generally recognized according to progress and milestones. The volume and types of work can be updated by the customer during execution. In addition, projects usually involve an advance against a bank guarantee, a performance guarantee of up to 5% of project consideration, and at completion a warranty guarantee of up to 5%.
In plain terms, this is not the kind of backlog that behaves like a subscription contract. Even when projects exist, the eventual profit depends on customer updates, execution pace, installation, pricing, and delivery quality. So the goodwill question cannot be answered only by pointing to NIS 18.2 million of backlog.
And the backlog itself is shrinking. Shinzon's backlog stood at about NIS 23.0 million at the end of 2024. It fell to about NIS 18.2 million at the end of 2025, and to NIS 16.5 million near the report date. Out of the year-end 2025 backlog, about NIS 16.2 million is expected to be recognized in 2026 and NIS 2.0 million in 2027. The company itself says it does not have reliable tools for a quarterly split of 2026 because of the project's nature.
The company explains that the decline versus the end of 2024 mainly reflects a deliberate focus on improving operating profitability in the project activity, even at the expense of sales. That may be the right move. It may even be the healthier move. If Shinzon gave up weaker volume in order to protect margin, that is better than chasing top line at any price. But at this stage it is still management's claim, not a delivered result. The 2025 filing still keeps an ongoing operating loss in the background, which means the transition from "less volume, better profit" has not yet been proven in the numbers.
The gap becomes even sharper when compared with the commercial-development story the company tells for the future. In its strategic objectives, the group identifies healthcare and nursing in Israel as a significant growth engine, in part through Clear and Shinzon, and refers to a market of roughly 500 nursing homes and assisted-living facilities and about 90 hospitals in Israel. Yet in the same filing, the disclosed backlog mix for Shinzon is described mainly as furniture and equipment for hygienic rooms sold to institutional customers in industry and commerce.
That does not prove the strategy is wrong. It does show that the commercial engine on which one could build optimism for 2027 and beyond is not yet fully visible in the disclosed backlog. So reading the value-in-use model as if it is already backed by a proven order book is too flattering a read of the filing.
| What still needs proof | What the filing already gives | What is still open |
|---|---|---|
| A shift from volume to profitability | Management says the smaller backlog reflects a focus on profitability | There is still no clean disclosed proof that the activity is already earning better |
| Visibility into 2026 | NIS 16.2m of backlog is slated for 2026 | There is no reliable quarterly split, and customers can update scope during execution |
| A healthcare and nursing growth engine | Management marks it as a target market through Shinzon | The current disclosed backlog is still described mainly as industry and commerce |
| Support for the goodwill balance | Recoverable amount is above carrying value | Headroom is only about NIS 1.6m and rests on a multi-year forecast path |
What Still Has to Go Right
First, Shinzon has to show better profitability on the smaller backlog base. As long as the backlog decline is framed as a conscious tradeoff in favor of profitability, the next filing has to start showing that in profit, not only in narrative.
Second, the backlog has to rebuild beyond 2026 without returning to work that weakens margin. Right now almost all visible coverage sits inside 2026, with only a small tail into 2027. That makes the activity highly sensitive to new order flow already during the coming year.
Third, the healthcare and nursing story has to move from the strategy section into the order book. As long as the disclosed backlog still sits mainly in industry and commerce, it is hard to give full weight to a growth assumption that likely depends on commercial expansion into another lane.
Fourth, the next impairment test will need to lean more on delivered performance and less on the model. That does not mean the goodwill must be written down. It does mean the market will look for less spreadsheet logic and more proof that the activity can actually turn short-cycle projects, guarantees, milestones, and customer changes into stable operating profit.
Bottom Line
Shinzon is not large enough to break Primotec, but it is large enough to show where the balance sheet is still ahead of operating proof. The goodwill survived 2025 because the value-in-use model still produced a recoverable amount above carrying value. That is valid in accounting terms. It still does not mean the activity has already proven what the model assumes.
The strongest counter-thesis is that this caution is too severe. After all, a NIS 1.628 million impairment was already taken in 2024, a 19.95% discount rate is still high, the current backlog is real, and the company explicitly says the backlog decline came from a focus on more profitable projects. It is entirely possible that the next filing will show that a smaller backlog base was exactly what the activity needed.
But as of the end of 2025, the more conservative read still looks stronger: Shinzon's future profitability remains unproven, and the goodwill still sitting on the balance sheet does not rest on a wide cushion. So what matters from here is not only whether more projects arrive, but whether there is better project economics. That will decide whether Shinzon stops being an assumption-heavy balance-sheet layer and becomes a real value layer inside the group.
Disclosure: Deep TASE analyses are general informational, research, and commentary content only. They do not constitute investment advice, investment marketing, a recommendation, or an offer to buy, sell, or hold any security, and are not tailored to any reader's personal circumstances.
The author, site owner, or related parties may hold, buy, sell, or otherwise trade securities or financial instruments related to the companies discussed, before or after publication, without prior notice and without any obligation to update the analysis. Publication of an analysis should not be read as a statement that any position does or does not exist.
The analysis may contain errors, omissions, or information that changes after publication. Readers should review official filings and primary sources before making decisions.